Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Clinical Ophthalmology (Auckland, N.Z.)|May 28, 2010
First-year treatment costs among new initiators of topical prostaglandin analogs: pooled resultsJordana K Schmier, David W Covert
Clinical Ophthalmology (Auckland, N.Z.)|December 10, 2009
Characteristics of respondents with glaucoma and dry eye in a national panel surveyJordana K Schmier, David W Covert
Clinical Ophthalmology (Auckland, N.Z.)|December 10, 2009
First-year treatment costs among new initiators of topical prostaglandin analogsJordana K Schmier, David W Covert, Alan L Robin
Transactions of the American Ophthalmological Society|January 28, 2003
Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjectsMichael T Halpern, David W Covert, Alan L Robin
Clinical Drug Investigation|November 10, 2012
Medical service encounters and payments associated with topical adjunctive therapy use of timolol for glaucomaJordana K Schmier, David W Covert, Edmund C Lau
Clinical Ophthalmology (Auckland, N.Z.)|October 20, 2010
Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogsJordana K Schmier, Edmund C Lau, David W Covert
Current Medical Research and Opinion|October 10, 2007
Estimated first-year costs of prostaglandin analogs with/without adjunctive therapy for glaucoma management: a United States perspectiveJordana K Schmier, David W Covert, Alan L Robin
American Journal of Ophthalmology|July 28, 2012
Patterns and costs associated with progression of age-related macular degenerationJordana K Schmier, David W Covert, Edmund C Lau
Current Medical Research and Opinion|February 24, 2009
First-year treatment patterns among new initiators of topical prostaglandin analogsJordana K Schmier, David W Covert, Alan L Robin
Pageof 3